People suffering from multiple food allergies may have more treatment options after scientists discovered an injectable ...

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical ...

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

Food allergy, intolerance, and sensitivity generally differ based on whether or not IgE, a protein the body can make against allergens, is involved in the reaction.

Discover the Clinical Support Tool, a significant advancement, integrating clear clinical criteria and epinephrine treatment guidelines.

Introducing baked eggs to infants aged 4–6 months and maintaining daily intake for six months significantly improves ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...

(MENAFN- GlobeNewsWire - Nasdaq) The global food allergy treatment market size is calculated at USD 7.47 billion in 2025 and is expected to reach around USD 15.32 billion by 2034, growing at a ...

This “leaky gut” can cause issues with digestion (constipation, diarrhea, gas and bloating), skin rashes, runny nose and ...

as well as the increasing role of oral immunotherapy and intranasal epinephrine in treatment plans. Traister discusses the impact of Xolair (omalizumab), now approved for food allergy, 1 and how it ...